SCHEMBL3958461

SCHEMBL3958461

Cc1nc(CO)nn1-c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 1/20 0.39
PTGS2 P35354 1/20 0.39
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
KMT2A Q03164 2/20 0.38
CYP1A2 P05177 1/20 0.38
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
POLB P06746 2/20 0.37
MAPT P10636 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030353 0.83 LMNA (0.48) CYP1A2LMNASMN1; SMN2NPC1RAB9A
SCHEMBL21893501 0.77 MAPK10 (0.46) PTGS2PSEN1PSEN2APH1BNCSTN
SCHEMBL2360545 0.74 MEN1 (0.46) PTGS2PSEN1PSEN2APH1BNCSTN
SCHEMBL5336030 0.73 MAPT (0.64) PTGS2KMT2ALMNASMN1; SMN2MEN1
SCHEMBL29204525 0.73 SMO (0.40) KMT2ALMNAMEN1POLBMAPT
SCHEMBL3356061 0.72 TDP1 (0.65) PTGS2KMT2ALMNASMN1; SMN2MEN1
SCHEMBL24655967 0.71 PPARA (0.41) PTGS2PSEN1PSEN2APH1BNCSTN
SCHEMBL21849226 0.71 PSEN1 (0.39) PTGS2PSEN1PSEN2APH1BNCSTN
SCHEMBL3954089 0.70 PTGS2 (0.39) PTGS2PSEN1PSEN2APH1BNCSTN
SCHEMBL15760229 0.70 KMT2A (0.76) KMT2ALMNASMN1; SMN2MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029559-B1 ARYL-4-ETHYNYL-ISOXAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-08-05 EP disclosed
US-7544704-B2 Aryl-4-ethynyl-isoxazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-06-09 US disclosed
EP-2029559-A1 ARYL-4-ETHYNYL-ISOXAZOLE DERIVATIVES F. Hoffmann-Roche AG (CH) 2009-03-04 EP disclosed
US-20070287739-A1 Aryl-4-ethynyl-isoxazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-12-13 US disclosed
WO-2007137954-A1 ARYL-4-ETHYNYL-ISOXAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287739-A1 Aryl-4-ethynyl-isoxazole derivatives GABRA5, GABRA4, GABRA1 GPR52 393/4885PTGS2 3774/4885PSEN1 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.